Citation Impact
Citing Papers
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
2017
Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors
2012
E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx— ECOG-ACRIN Cancer Research Group
2017
PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer
2017
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
2011
Human Papillomavirus and Overall Survival After Progression of Oropharyngeal Squamous Cell Carcinoma
2014
Cabozantinib in Progressive Medullary Thyroid Cancer
2013
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
2017
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Bifluoride Ion Mediated SuFEx Trifluoromethylation of Sulfonyl Fluorides and Iminosulfur Oxydifluorides
2019 StandoutNobel
Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study
2017
Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine
2014
Cancer immunotherapies targeting the PD-1 signaling pathway
2017 StandoutNobel
Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
2015
Head and neck squamous cell carcinoma
2020 Standout
Clinical update on head and neck cancer: molecular biology and ongoing challenges
2019
Head and neck cancers—major changes in the American Joint Committee on cancer eighth edition cancer staging manual
2017 Standout
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
2020
A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging
2018
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
2017 Standout
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
A view on drug resistance in cancer
2019 StandoutNature
Thyroid cancer
2016 Standout
Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
2013
Immune Checkpoint Inhibitor Toxicity in Head and Neck Cancer: From Identification to Management
2019
Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
2017
Ovarian cancer
2014 Standout
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
2019 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer
2017
Transforming Growth Factor-β Signaling in Immunity and Cancer
2019 Standout
Heterogeneity of the Head and Neck Squamous Cell Carcinoma Immune Landscape and Its Impact on Immunotherapy
2019
Hallmarks of aging: An expanding universe
2023 Standout
Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment
2016 Standout
Guillain-Barré syndrome
2016 Standout
Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
2017
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
2016 Standout
Targeted therapy in rare cancers—adopting the orphans
2012
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
2017 Standout
Nasopharyngeal carcinoma
2019 Standout
T Cell Dysfunction in Cancer
2018
Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy
2016 StandoutNobel
Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer
2020
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
2017 Standout
Thyroid Gland Malignancies
2015
Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials
2015
Lung cancer: current therapies and new targeted treatments
2016 Standout
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
2011 Standout
Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer
2015
Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4
2019
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Sex and gender: modifiers of health, disease, and medicine
2020 Standout
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
2015
Frameshift events predict anti–PD-1/L1 response in head and neck cancer
2018
Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy
2018
Anchor extension: a structure-guided approach to design cyclic peptides targeting enzyme active sites
2021 StandoutNobel
Drug development in the era of precision medicine
2017
Mortality due to cancer treatment delay: systematic review and meta-analysis
2020 Standout
The head and neck cancer immune landscape and its immunotherapeutic implications
2016
Genomic insights into head and neck cancer
2016
Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition
2013
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials
2018
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
2015 Standout
Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches
2011
Patient-Derived Xenografts for Prognostication and Personalized Treatment for Head and Neck Squamous Cell Carcinoma
2018
Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation
2019
Prospects for MEK inhibitors for treating cancer
2014
The molecular landscape of head and neck cancer
2018 Standout
New treatment strategies for HPV-positive head and neck cancer
2013
Antiangiogenic therapy in oncology: current status and future directions
2016
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
2018 Standout
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
2016
The PI3K Pathway in Human Disease
2017 Standout
Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study
2017
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Comprehensive Integration of Single-Cell Data
2019 Standout
Innate immune signaling and regulation in cancer immunotherapy
2016
A phase I study of cabozantinib (XL184) in patients with renal cell cancer
2014 StandoutNobel
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial
2013
Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity
2017
Targeting MET in cancer: rationale and progress
2012
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
2018
Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies
2014
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 Standout
Human papillomavirus-related oropharyngeal cancer
2017
Clinical, Safety, and Economic Evidence in Radioactive Iodine–Refractory Differentiated Thyroid Cancer: A Systematic Literature Review
2013
Extrathyroidal Extension Predicts Extranodal Extension in Patients with Positive Lymph Nodes: An Important Association That May Affect Clinical Management
2014
Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma
2015 Standout
BRAF Inhibitor Dabrafenib in Patients with Metastatic BRAF -Mutant Thyroid Cancer
2014
A Phase I Study of Cabozantinib (XL184) in Patients with Differentiated Thyroid Cancer
2014
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Taxane-Cisplatin-Fluorouracil As Induction Chemotherapy in Locally Advanced Head and Neck Cancers: An Individual Patient Data Meta-Analysis of the Meta-Analysis of Chemotherapy in Head and Neck Cancer Group
2013
Hepatocellular Carcinoma
2019 Standout
Neurological Complications Associated With Anti–Programmed Death 1 (PD-1) Antibodies
2017
Cabozantinib Inhibits Growth of Androgen-Sensitive and Castration-Resistant Prostate Cancer and Affects Bone Remodeling
2013
Immune checkpoint inhibitors: new strategies to checkmate cancer
2017
Head and Neck Cancer
2020 Standout
Targeting ALK: Precision Medicine Takes on Drug Resistance
2017
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study
2015
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
2018 Standout
The role of transoral robotic surgery, transoral laser microsurgery, and lingual tonsillectomy in the identification of head and neck squamous cell carcinoma of unknown primary origin: A systematic review
2016
Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality‐of‐life assessments
2014
Vaccine innovations for emerging infectious diseases—a symposium report
2019 StandoutNobel
Telomere-mediated lung disease
2022
Gene targets of sulforaphane in head and neck squamous cell carcinoma
2019
The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
2018 StandoutScience
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
2018
Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study
2017
Safety of Bevacizumab in Patients with Advanced Cancer: A Meta-Analysis of Randomized Controlled Trials
2010
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
HDACs and HDAC Inhibitors in Cancer Development and Therapy
2016
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
2015
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
2017 Standout
Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma
2017
Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
2015
ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it.
2014
Treatment at high‐volume facilities and academic centers is independently associated with improved survival in patients with locally advanced head and neck cancer
2017
A Dose-Ranging Study of Cabozantinib in Men with Castration-Resistant Prostate Cancer and Bone Metastases
2013
Works of Ranee Mehra being referenced
Phase II Study of Cetuximab in Combination with Cisplatin and Radiation in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma: Eastern Cooperative Oncology Group Trial E3303
2014
Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements
2012
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012
2018
A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma
2015
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
2016 Standout
Aurora kinases in head and neck cancer
2013
Incidence and management of bevacizumab-related toxicities in colorectal cancer
2006
Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy
2018
Targeting brain metastases in ALK-rearranged non-small-cell lung cancer
2015
Increased Recurrences Using Intensity-Modulated Radiation Therapy in the Postoperative Setting
2010
Genetic landscape of patients with ALK-rearranged non–small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study
2021
Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials
2014
Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer
2011
Extranodal Extension of Metastatic Papillary Thyroid Carcinoma: Correlation with Biochemical Endpoints, Nodal Persistence, and Systemic Disease Progression
2013
The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck.
2008
Results of a First-In-Human Phase I Study of the Alk Inhibitor LDK378 in Advanced Solid Tumors
2012
Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial
2017
2866 Antitumor activity of the Anti-PD-1 antibody pembrolizumab in subgroups of patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Exploratory analyses from KEYNOTE-012
2015
Comment on “Epidermal Growth Factor Receptor Is Essential for Toll-Like Receptor 3 Signaling”
2012
Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors
2017
Genetic landscape of ALK+ non-small cell lung cancer (NSCLC) patients (pts) and response to ceritinib in ASCEND-1.
2016
Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial.
2014
Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
2011
Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort.
2015
Evaluation of Ceritinib-Treated Patients (Pts) with Anaplastic Lymphoma Kinase Rearranged (Alk+) Non-Small Cell Lung Cancer (Nsclc) and Brain Metastases in the Ascend-1 Study
2014
DeCIDE: A phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN).
2012
Inflamed-phenotype gene expression signatures to predict benefit from the anti-PD-1 antibody pembrolizumab in PD-L1+ head and neck cancer patients.
2015
Abstract LB-339: Biomarkers predictive of response to pembrolizumab in head and neck cancer (HNSCC)
2018
Survival Impact of Increasing Time to Treatment Initiation for Patients With Head and Neck Cancer in the United States
2015
A phase 1b/2a, multi-center, open-label study to evaluate the safety and efficacy of combination treatment with MEDI0457 (INO-3112) and durvalumab (MEDI4736) in patients with recurrent/metastatic human papilloma virus–associated head and neck squamous cell cancer.
2018
HPV Association and the Increasing Incidence of Unknown Primary Head-and-Neck Squamous Cell Carcinoma
2014
p16 status, pathologic and clinical characteristics, biomolecular signature, and long‐term outcomes in head and neck squamous cell carcinomas of unknown primary
2013
Ovarian Failure Preceding Head and Neck Squamous Cell Carcinoma Identifies an Adult-Onset Cancer-Prone Syndrome Caused by FANCM Mutations
2021
Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
2016
Genomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma (HNSCC).
2017
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Pooled analyses after long-term follow-up in KEYNOTE-012.
2016
Phospho-T356RB1 predicts survival in HPV-negative squamous cell carcinoma of the head and neck
2015